This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e. g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to Phase 1 or Phase 2 studies utilising experimental medicine.
Inhaltsverzeichnis
Translational mouse models of autism; Advancing towards pharmacological therapeutics. - Translatable and back-translatable measurement of impulsivity and compulsivity; convergent and divergent processes. - Translational models of gambling-related decision-making. - Translational research on nicotine dependence. - The need for treatment-responsive translatable biomarkers in alcoholism research. - On the road to translation for PTSD treatment: theoretical and practical considerations of the use of human models of conditioned fear for drug development. - Translational approaches targeting reconsolidation. - Translational assessment of reward and motivational deficits in psychiatric disorders. - Affective biases in humans and animals. Robinson. - Locomotor profiling from the rodents to the clinic and back again. - Animal models of sensori-motor gating in schizophrenia: Are they still relevant? . - Attention and the cholinergic system: relevance to schizophrenia. - Attentional-set-shifting across species. - Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery. - Cognitive translation using the rodent touchscreen test approach. - The Paired Associates Learning (PAL) Test: 30 years of CANTAB Translational Neuroscience From Laboratory to Bedside in Dementia Research. - Translational approaches to experimental medicine.